Ensovibep COVID-19 studies. Ensovibep requires IV infusion, but may be less variant dependent than monoclonal antibodies.
Submit updates/corrections .
Jun 7 |
(Preprint) (meta analysis) | Ensovibep for COVID-19: real-time meta analysis of 2 studies |
| Statistically significant improvement is seen for hospitalization. One study shows statistically significant improvement in isolation (not for the most serious outcome). • Meta analysis using the most serious outcome reported shows.. | ||
Aug 9 |
et al., Annals of Internal Medicine, doi:10.7326/M22-1503 | Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 |
| 17% lower mortality [p=0.46], 6% improved recovery [p=0.55], and 7% higher hospital discharge [p=0.46]. RCT 485 hospitalized patients showing no significant differences with ensovibep treatment. Intravenous ensovibep, 600mg. | ||
Jan 10 |
Press Release (News) | Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 |
| 89% lower mortality [p=0.06], 87% lower hospitalization [p=0.01], and 78% fewer combined hospitalization/ER visits [p=0.02]. EMPATHY Part A RCT with 407 patients, 301 treated with ensovibep, showing statistically significant viral load reduction (details not provided), and lower mortality and hospitalization. For discussion see [twitter.com]. | ||
Nov 16 2021 |
, Press Release (News) | Molecular partners provides update from ACTIVE-3 global clinical study of ensovibep in patients hospitalized with COVID-19 |
| no change in recovery [p=1]. News release reporting that ensovibep was terminated for futility in ACTIV-3. 470 patients had been randomized. | ||
Feb 3 2021 |
et al., bioRxiv, doi:10.1101/2021.02.03.429164 (Preprint) (In Vitro) | Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants |
| In Silico, In Vitro, and hamster study of ensovibep, a DARPin candidate that can engage all three units of the spike protein trimer to inhibit ACE2 interaction, showing efficacy for common variants, and efficacy comparable to casirivimab/.. | ||
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.